ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04933682
- Locations
- 🇺🇸
Clinical Trial Site, Tempe, Arizona, United States
Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ALXN1720 IVDrug: ALXN1720 SCDrug: Placebo SCDrug: rHuPH20Drug: Placebo IV
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT04920370
- Locations
- 🇬🇧
Clinical Study Site, London, United Kingdom
Study of Radiolabeled Danicopan in Healthy Male Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: [14C]-Danicopan
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT04889391
- Locations
- 🇳🇿
Clinical Trial Site, Auckland, New Zealand
Study of Multiple Doses of Danicopan in Healthy Participants
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT04889690
- Locations
- 🇳🇿
Clinical Trial Site, Auckland, New Zealand
Study of a Single Dose of Danicopan in Healthy Participants
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT04889677
- Locations
- 🇳🇿
Clinical Trial Site, Auckland, New Zealand
COVID-19 Soliris Expanded Access Protocol
- Conditions
- Covid19
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT04802083
Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib
- Conditions
- Relapsed/Refractory Chronic Lymphocytic LeukemiaNon-hodgkin's Lymphoma
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT04757259
A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome
Phase 3
Completed
- Conditions
- Guillain-Barre Syndrome
- Interventions
- Biological: EculizumabDrug: Placebo
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT04752566
- Locations
- 🇯🇵
Clinical Trial Site, Yokohama, Japan
Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
Phase 3
Terminated
- Conditions
- Thrombotic Microangiopathy
- Interventions
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04743804
- Locations
- 🇬🇧
Research Site, Stevenage, United Kingdom
A Study of ALXN1830 in Healthy Adult Participants
Phase 1
Terminated
- Conditions
- Healthy
- Interventions
- Drug: ALXN1830Drug: Placebo
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04730804
- Locations
- 🇳🇿
Research Site, Grafton, New Zealand
🇳🇿Clinical Trial Site, Auckland, New Zealand
© Copyright 2025. All Rights Reserved by MedPath